Topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines

Total thirty-six dihydroxylated 2,6-diphenyl-4-aryl pyridines were designed, synthesized and tested for topo I and II inhibitory activity and cytotoxicity for the development of novel anticancer agents. [Display omitted] A new series of thirty-six dihydroxylated 2,6-diphenyl-4-aryl pyridines contain...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry Vol. 23; no. 13; pp. 3638 - 3654
Main Authors: Karki, Radha, Song, Chanju, Kadayat, Tara Man, Magar, Til Bahadur Thapa, Bist, Ganesh, Shrestha, Aarajana, Na, Younghwa, Kwon, Youngjoo, Lee, Eung-Seok
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-07-2015
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Total thirty-six dihydroxylated 2,6-diphenyl-4-aryl pyridines were designed, synthesized and tested for topo I and II inhibitory activity and cytotoxicity for the development of novel anticancer agents. [Display omitted] A new series of thirty-six dihydroxylated 2,6-diphenyl-4-aryl pyridines containing hydroxyl groups at the ortho, meta, or para position of 2- and 6-phenyl rings attached to the central pyridine were designed and synthesized. They were evaluated for topoisomerase I and II inhibitory activity and cytotoxicity against several human cancer cell lines for the development of novel anticancer agents. Most of the compounds with hydroxyl moiety either at the meta or para position of 2- or 6-phenyl ring in combination with thienyl or furyl group at 4-position of central pyridine displayed significant topoisomerase II inhibitory activity and cytotoxicity. Positive correlation between topoisomerase II inhibitory activity and cytotoxicity was observed for the compounds 9–11, 15–17, 19, 21–23, 28, and 41. Among all the synthesized compounds, compound 17 emerged as the most promising topoisomerase II inhibitor with significant cytotoxicity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2015.04.002